Karyopharm TherapeuticsKPTI
About: Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
Employees: 325
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
1,266% more call options, than puts
Call options by funds: $929K | Put options by funds: $68K
6.72% less ownership
Funds ownership: 54.37% [Q2] → 47.65% (-6.72%) [Q3]
16% less capital invested
Capital invested by funds: $58.8M [Q2] → $49.2M (-$9.58M) [Q3]
20% less funds holding
Funds holding: 113 [Q2] → 90 (-23) [Q3]
28% less repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 29
70% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 33
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Piper Sandler Christopher Raymond 19% 1-year accuracy 5 / 27 met price target | 683%upside $5 | Overweight Maintained | 6 Nov 2024 |
HC Wainwright & Co. Edward White 24% 1-year accuracy 34 / 139 met price target | 997%upside $7 | Buy Reiterated | 6 Nov 2024 |
Financial journalist opinion
Based on 4 articles about KPTI published over the past 30 days